News

Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.

CYTK enters a new era after Myqorzos FDA approval, with early US uptake, European expansion and lifecycle studies fueling its commercial momentum.

Pfizer's (PFE) second-quarter revenue is expected to match Wall Street's estimates, while its earnin

Bristol-Myers Squibb (BMY) was recently removed from several Russell growth benchmarks and added to the Russell 1000 Defensive and Russell 1000 Value-Defensive indices, shifting how many institutional investors may gain exposure to the stock. See our latest analysis for Bristol-Myers Squibb. At a share price of US$57.54, Bristol-Myers Squibb has seen mixed short term moves, with the 7 day share price return of 1.95% and 30 day share price return of 3.55% contrasting with a 90 day decline of...

Prothena shares climb as late-stage partnered programs advance, milestone payments strengthen finances and its neurodegenerative pipeline continues to expand.

Get paid a guaranteed income now on your Amgen shares, which you keep no matter what, in exchange for agreeing to sell at a price that's already a win.

Bristol Myers Squibb (NYSE:BMY) Foundation’s QUILS initiative is reshaping lung cancer early detection in Kentucky. The program is now serving as a model for similar efforts in Mississippi and Nevada. QUILS targets earlier identification of lung cancer in regions with some of the highest reported rates in the country. Bristol Myers Squibb operates as a global biopharmaceutical company with a focus on oncology, immunology, and cardiovascular treatments. The QUILS initiative adds a public...

AbbVie's stock commands a king's ransom, but its performance metrics rule the kingdom, leaving investors to ask if they are buying at the top of the reign.

Bristol-Myers Squibb is expected to report its second-quarter earnings later this month, and Wall Street is calling for a double-digit decrease in profit.

In late June 2026, Janux Therapeutics, Inc. was removed from several Russell growth and small-cap benchmarks, including the Russell 2000 Growth, 2500 Growth, Small Cap Comp Growth, 3000E Growth, and 3000 Growth indexes. This broad index removal matters because it can force index-tracking funds to rebalance, potentially changing who holds the stock and how it trades. Next, we’ll examine how Janux’s removal from multiple Russell growth indexes shapes the company’s investment narrative for...

SLS009 traces back to Sellas’ 2022 GenFleet licensing deal, when the company obtained rights outside Greater China to GFH009, now known as SLS009.

In late June 2026, Bristol-Myers Squibb was removed from several Russell growth benchmarks and added to the Russell 1000 Value-Defensive and Russell 1000 Defensive indices, marking a reclassification of the stock within major index families. This shift signals that index providers now view Bristol-Myers Squibb more as a defensive, income-oriented holding than a growth-driven pharmaceutical name, aligning with its dividend profile and efforts to manage patent expirations. Next, we will...

Bristol-Myers Squibb stock has logged a solid 29.2% return over the past year, yet its valuation checks point to a mixed picture rather than a straightforward bargain or an obviously expensive share price. The 29.2% gain over the past 12 months puts recent shareholders in a strong position, raising the question of how much of the good news is already reflected in the price. Investor attention on new oncology and cardiology programs, including recent trial collaborations and regulatory...

They may not remain cheap for too much longer.

Finding stocks with generous dividends isn’t easy these days, and with packaged food giant Conagra recently getting demoted from the S&P 500, Pfizer is now the highest yielding stock in the benchmark index. The drug company, which has made quarterly payouts more than 80 straight years, is certain to get a lot of attention from dividend hunters. Pfizer’s high yield reflects investors’ trepidation over the stock.

This big pharma stock looks attractive for income investors -- but it comes with some risk.

RHHBY announces positive phase III Krascendo 1 results for divarasib in KRAS G12C NSCLC, showing PFS and OS gains versus approved inhibitors.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index and the State

Healthcare stocks were higher Thursday afternoon, with the NYSE Healthcare Index rising 2% and the S

Five of the biggest names in American pharma just got a deadline from Washington. The House Select Committee on China sent letters this week to Merck (MRK), AbbVie (ABBV), Eli Lilly (LLY), Pfizer (PFE), and Bristol Myers Squibb (BMY), Reuters reported. Lawmakers want each company to explain ...

The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.

Bristol-Myers Squibb Company (NYSE:BMY) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 3, Arcus Biosciences announced a clinical trial collaboration and supply agreement with Bristol-Myers Squibb Company (NYSE:BMY), where Arcus’s investigational kidney cancer drug, casdatifan, will be added to Bristol-Myers’s ongoing Phase 1/2 ROSETTA RCC-208 trial. The trial focuses on […]

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Bristol Myers Squibb trades at a deep discount, while Johnson & Johnson boasts higher margins and a broader reach. How do their financials and risks stack up?

Bristol-Myers Squibb (NYSE:BMY) has been added to the Russell 1000 Value Defensive and Russell 1000 Defensive Indexes. At the same time, the company has been removed from several growth-focused Russell benchmarks. This reclassification marks a shift in how major indexes group Bristol-Myers Squibb within the market. Bristol-Myers Squibb, a large US-based pharmaceutical company, now sits firmly in the value and defensive camp within the Russell index family. For investors who follow NYSE:BMY,...

A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country’s military capabilities, according to a...

We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Bristol-Myers Squibb Company (NYSE:BMY) is one of the best low-priced pharma stocks on this list. TheFly reported on June 15 that RBC Capital analyst Trung Huynh noted that the proposed changes to the Medicare Drug Price Negotiation Program could introduce potential […]

The company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of Bristol Myers drugs.